(Drug Name) (Drug Form) (Drug Strength)
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

NUVESSA: Vaginal gel (1.3%)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
NUVESSA 1.3% Vaginal Gel

What is this Medicine?

METRONIDAZOLE (me troe NI da zole) VAGINAL GEL is an antiinfective. It is used to treat bacterial vaginitis.

CVS Pharmacy Patient Statistics for NUVESSA: Vaginal gel(1.3%)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information
Select a Medication

NUVESSA 1.3% Vaginal Gel

NDC: 525440157
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Bacterial Vaginosis

Storage Information
Do not refrigerate
Protect from freezing
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
NUVESSA 1.3% Vaginal Gel

Reported Side Effects for NUVESSA 1.3% Vaginal Gel

Lightheadedness Incidence:
<4.0%*
Severity: MILD
Onset: EARLY
Diaphoresis Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Increase In Breast Size Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Back Pain Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Vomiting Incidence:
<4.0%*
Severity: MILD
Onset: EARLY
Acne Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Heavy Menstrual Period Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Rhinitis Incidence:
<4.0%*
Severity: MILD
Onset: EARLY
Vaginal Discharge Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Increased Urination Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Painful Urination Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Inability To Sleep Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Gum Inflammation Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Gas Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Depression Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Constipation Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Decreased Appetite Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Hives Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Infection Incidence:
<7.0%*
Severity: MILD
Onset: DELAYED
Flu Incidence:
<6.0%*
Severity: MILD
Onset: DELAYED
Vaginal Infection Incidence:
<15.0%*
Severity: MODERATE
Onset: DELAYED
Yeast Infection Incidence:
0.2-12.0%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
1.0-4.0%*
Severity: MILD
Onset: EARLY
Stuffy Nose Incidence:
1.1%*
Severity: MILD
Onset: EARLY
Menstrual Cramps Incidence:
1.2-3.0%*
Severity: MILD
Onset: DELAYED
Sinus Infection Incidence:
1.4-3.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
1.6-10.0%*
Severity: MILD
Onset: EARLY
Itching Incidence:
1.6-6.0%*
Severity: MILD
Onset: RAPID
Metallic Taste Incidence:
2.0-9.0%*
Severity: MILD
Onset: EARLY
Metallic Taste Incidence:
2.0-9.0%*
Severity: MILD
Onset: EARLY
Dry Mouth Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Sore Throat Incidence:
2.0-3.1%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
2.2-18.0%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
4.0-5.0%*
Severity: MILD
Onset: EARLY
Itching Around The Anus Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Vaginal Irritation Incidence:
>9.0%*
Severity: MILD
Onset: EARLY
Vaginal Discharge Incidence:
12.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
First Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Second Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Third Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with NUVESSA

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5